Abstract: Aspects of the present disclosure relates to genetically altered LysM receptors. In particular, the present disclosure relates to a hydrophobic patch into the LysM2 domain which can increase affinity and/or selectivity for LCOs and by replacement of regions in the LysM1 domain with the corresponding regions of the LysM1 domain from a donor LysM receptor that can alter the affinity and/or selectivity for the oligosaccharide particularly for LCOs and can alter the specificity between LCO when using regions from a high affinity and specificity LCO LysM receptor such as a legume NFR1 receptor. The present disclosure also relates to genetically altering LysM receptors in plants to include a hydrophobic patch or alter the hydrophobic patch and to genetically altering LysM receptors in plants by replacement of regions in the LysM2 domain.

Abstract: Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well as methods of treating disorders associated with complement activation.

Abstract: Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well as methods of treating disorders associated with complement activation.

Abstract: Compounds and methods for treating infertility or reduced fertility in a female individual are provided, wherein a method includes taking primordial follicles from said individual, treating said follicles in vitro with an NRF2 modulator and re-inserting the treated follicles into said individual. An in vitro method of regulating primordial follicle maturation is provided, wherein the method includes contacting primordial follicles and an NRF2 modulator.

Abstract: Aspects of the present disclosure relates to genetically altered LysM receptors. In particular, the present disclosure relates to a hydrophobic patch into the LysM2 domain which can increase affinity and/or selectivity for LCOs and by replacement of regions in the LysM1 domain with the corresponding regions of the LysM1 domain from a donor LysM receptor that can alter the affinity and/or selectivity for the oligosaccharide particularly for LCOs and can alter the specificity between LCO when using regions from a high affinity and specificity LCO LysM receptor such as a legume NFR1 receptor. The present disclosure also relates to genetically altering LysM receptors in plants to include a hydrophobic patch or alter the hydrophobic patch and to genetically altering LysM receptors in plants by replacement of regions in the LysM2 domain.

Abstract: The present disclosure relates to modified plant SYMRK polypeptides that constitutively induces symbiotic organogenesis or induces symbiotic organogenesis in the absence of rhizobial bacteria and/or arbuscular mycorrhizal fungi recognized by the plant at a higher level than the unmodified plant SYMRK polypeptide under the same conditions and use thereof in plants.

Abstract: The present invention relates to a composition comprising a first gRNA bound to an RNA-guided endonuclease forming a first ribonucleoprotein complex, said first gRNA comprises a first targeting sequence being complementary for a first target sequence in an intron in the 5? upstream part of a fusion gene; and a second gRNA bound to an RNA-guided endonuclease forming a second ribonucleoprotein complex, said second gRNA comprises a second targeting sequence being complementary for second target sequence in an intron in the 3? downstream part of the fusion gene. Such compositions may find use in the treatment of fusion gene related cancers.

Abstract: The present disclosure relates to modified plant LysM receptor polypeptides with modified intracellular domains, specifically, modified ?A motifs and/or modified ?A? motifs in the juxtamembrane domain. The present disclosure further relates to genetically modified plants including the modified plant LysM receptor polypeptides, and methods of producing the same.

Abstract: The present disclosure relates to genetically modified plant LysM receptors and methods of producing the same. In particular, the present disclosure relates to modified plant LysM receptors including a modified juxtamembrane (JM) zone 4, and optionally further including a modified JM zone 2, a modified JM zone 3, a modified extracellular domain, and/or a modified kinase C-terminus region or a modified kinase N-terminus region. The modified LysM receptors of the present disclosure are either able to able to initiate NFR1-mediated root nodule symbiosis signaling or able to initiate ROS signaling. In addition, the present disclosure relates to genetically modified plants or parts thereof including the genetically modified plant LysM receptors and methods of producing the same. The present disclosure further relates to expression vectors, isolated DNA molecules, or recombinant nucleic acids encoding the genetically modified plant LysM receptors.

Abstract: Single domain antibodies are provided, which are capable of specifically binding to an epitope of a human complement factor selected from the group consisting of C1q, C3, C4 and/or the proteolytic derivatives C3b and C4b. Further the use of the antibodies are provided for methods in modulating the activity of the complement system as well 5 as methods of treating disorders associated with complement activation.

Abstract: The present invention relates to Rufinamide (or active derivatives thereof) for use in the treatment of myotonia, such as myotonia congenita, paramyotonia congenita and myotonic dystrophy. The present invention also relates to a combinatorial composition comprising Rufinamide (or active derivatives thereof) and Lamotrigine (or active derivatives thereof) for use as a medicament.

Abstract: The present disclosure relates to enhancing nitrogen fixation in legumes grown under high nitrate or nitrate stress conditions. In particular, the present disclosure relates to genetically modified plants with altered level or expression of FUN or FUN downstream targets, and methods of producing and growing the same. The present disclosure further relates to nodule senescence controlled by FUN and its downstream targets, as well as the regulation of FUN activity or expression by cellular zinc.

Abstract: The present invention relates to Rufinamide (or active derivatives thereof) for use in the treatment of myotonia, such as myotonia congenita, paramyotonia congenita and myotonic dystrophy. The present invention also relates to a combinatorial composition comprising Rufmamide (or active derivatives thereof) and Lamotrigine (or active derivatives thereof) for use as a medicament.

Abstract: The present disclosure relates to synthetic approaches based on affinity peptides to drive assembly and activation of transmembrane receptor complexes. The present disclosure further relates to the core NFR1-NFR5 receptor complex initiating the cortical root nodule organogenesis program and the epidermal program, as well as the identification of barley receptor complexes that function in root nodule symbiosis.

Abstract: An audio system adapted to provide an auditory stimulation for inducing neural oscillations in a user during sleep.

Abstract: A compound and methods are provided for treating, preventing or ameliorating infertility or reduced fertility in an individual, wherein said compound is capable of regulating the activity of Nuclear Factor, Erythroid 2 Like 2 (NFE2L2).

Abstract: The present invention relates to glycosylated YghJ polypeptides from or derived from enterotoxigenic Escherichia coli (ETEC) that are immunogenic. In particular, the present invention relates to compositions or vaccines comprising the polypeptides and their application in immunization, vaccination, treatment and diagnosis of ETEC.

Abstract: The invention relates to a genetically modified cereal plant having a recombinant DNA construct comprising a gene encoding a polypeptide having aspartyl protease activity (EC 3.4.23.12) whose expression, particularly in grain, confers enhanced fungal disease resistance as compared to a parent cereal plant from which said genetically modified cereal plant was derived. The invention further relates to a method for producing a genetically modified cereal plant of the invention comprising transforming one or more cells of a parent cereal plant with the recombinant DNA construct; as well as a method for manufacturing the genetically modified grain for production of a crop of genetically modified cereal plants which exhibit increased resistance to a fungal disease due to expression of the recombinant DNA construct.

Abstract: The present invention relates to methods for determining endonuclease activity in a sample. In particular, the present invention relates to a method for determining viable pathogenic bacteria in a sample based on patterns of endonuclease activity.

Abstract: The present invention concerns uses of immune suppressive domains. In particular, the present invention concerns a use of an immune suppressive domain (ISD) for immune suppression and for reduction of inflammation.